The Phase 2 grant is for work the company is doing to analyze the proteomic responses of immune cells in patients with Alzheimer's and related conditions.
In PLOS this week: transcriptomics-based strategy to study Alzheimer's disease heterogeneity, insecticide resistance diversity and evolution, and more.
The company's adaptive low-resource testing technology requires no instrumentation and limited equipment, making it adaptable to settings without clinical lab infrastructure.
The study also found that certain genes may influence multiple complex traits, while others only affect one phenotype, making them worthwhile therapeutic targets.
People with the APOE e4 gene variant who are at an increased risk for Alzheimer's disease but who are also heterozygous for a Klotho haplotype may have a reduced disease risk, a new study has found.
The company will offer a 32-gene polygenic score test to patients in the Osaka, Japan Nakanoshima Clinic, with reporting and patient support help from IxLayer.
The five-year initiative aims to collect and disseminate genomic data on 1 million people with Alzheimer's disease or who are at risk for the condition.
Florida Politics reports Florida's law barring life, long-term care, and disability insurers from using genetic information in coverage decisions went into effect at the beginning of July.
